blood Archives - Amazing Health Advances

Avoid Deadly Blood Clots with Two Natural Extracts

The AHA! Team — Mon, 25 Aug 2025 05:27:07 +0000

Lori Alton via NaturalHealth365 – According to the Centers for Disease Control and Prevention (CDC), as many as 900,000 Americans could be affected by venous thromboembolisms (blood clots) every year – with roughly 100,000 dying from them. Believe it or not, the simple act of sitting – for long periods – may be hazardous to your health. The American College of Cardiology reports that sitting at a desk for more than four hours a day increases the odds of deep vein thrombosis by a frightening 48 percent. Deep vein thrombosis, or DVT, occurs when a blood clot forms in a vein located deep in the body. In a life-threatening complication, the clot may break loose and make its way to the lung, leading to a potentially fatal pulmonary embolism. Fortunately, recent research shows that you can combat DVT – safely and effectively – with the help of two natural extracts. Blood clots affect close to one million Americans According to the Centers for Disease Control and Prevention (CDC), as many as 900,000 Americans could be affected by venous thromboembolisms (blood clots) every year – with roughly 100,000 dying from them. In fact, the risks of prolonged sitting are so pronounced many are calling sitting “the new smoking.” In truth, Western medicine offers few real solutions. Anticoagulant medications prescribed by conventionally trained doctors can feature serious side effects – along with the risk of hemorrhage or uncontrolled bleeding. However, recent research shows that two natural substances, French maritime pine bark extract, and nattokinase, can break down small clots before they grow – and even stop them from forming in the first place. Both can inhibit clotting, improve microcirculation in the legs, and increase the elasticity of blood vessel walls. What are the symptoms and signs of a blood clot? Unfortunately, about half the time, there are no apparent signs of deep vein thrombosis. When symptoms occur, they tend to develop suddenly – and can include swelling, fatigue, tenderness, and pain in the affected leg. Reddened skin, otherwise discolored skin, and warm skin on one or both legs can also be warning signs. A previously invisible vein that suddenly becomes visible is also a red flag that may indicate a possible blood clot. Call your doctor if you notice any of these warning signs – especially if they develop suddenly. Of course, aging can make you more susceptible to blood clots – especially when living a sedentary lifestyle. Being obese, smoking cigarettes, having surgery, and taking oral contraceptives can also raise your risk. French maritime pine bark extract: A powerful natural vasodilator Pine bark extract, also known as pycnogenol, is rich in beneficial polyphenols, including procyanidins and phenolic acids. With potent antioxidant and anti-inflammatory properties, pine bark extract dilates blood vessels and reduces blood platelets’ stickiness, making them less likely to form clots. French maritime pine bark extract also increases the activity of an enzyme that generates beneficial nitric oxide in blood vessels. Several studies have demonstrated that pine bark extract is especially effective in preventing blood clots from forming after prolonged sitting. French maritime pine bark extract has also been shown to help reduce post-thrombotic syndrome, a common DVT complication in which blood collects in the affected leg and causes swelling, discoloration, and leg ulcers. In a year-long study, French maritime pine bark extract was found to be at least as effective as compression stockings in treating post-thrombotic syndrome. Not only did no new cases occur in the participants who took pine bark extract, but leg and ankle swelling was significantly decreased when compared to the compression stockings group. Researchers concluded that pine bark extract may have significant long-term protective effects following a thrombotic event. Another plus for French maritime pine bark extract is that compliance was better in the pine bark group. Researchers noted that taking the extract was not as “bothersome” to the participants as wearing the compression stockings, especially in warm weather. Nattokinase: A potent protector made from soy Nattokinase is a proteolytic enzyme made from soybeans fermented with a specific bacterium, Bacillus subtilis. It helps to prevent clotting by breaking down fibrin – the main protein found in clots – and also breaks down fibrinogen, the precursor to fibrin. It achieves this without causing side effects or undesirable bleeding. Nattokinase, combined with pine bark extract, has produced impressive results in studies. In a randomized, placebo-controlled human trial published in Angiology, passengers on a lengthy overseas flight were given either a placebo or a nattokinase and pine bark extract combination. The combination prevented each and every passenger who took it from experiencing DVTs. While there were zero DVTs in the supplement group, 5.4 percent of the passengers in the placebo group did experience DVTs. In contrast to the supplement group, passengers in the placebo group experienced a 12 percent increase in leg swelling during the flight – while supplemented passengers actually enjoyed a 15 percent reduction. The conclusion is that nattokinase and French maritime pine bark extract helped to prevent deep vein thrombosis in people who spent long periods sitting – thereby reducing the threat of sudden death from pulmonary embolism. If you must sit at a desk for prolonged periods, experts recommend getting up every hour and walking around for at least five to ten minutes to prevent blood from pooling in your legs. If interested, we suggest you discuss nattokinase and pine bark extract supplementation with your holistic healthcare provider. And, if they don’t know about these substances – find a doctor who understands the value of natural remedies. Sources for this article include: NIH.gov Lifeextension.com Globalhealing.com NIH.gov NIH.gov To read the original article click here.

The post Avoid Deadly Blood Clots with Two Natural Extracts appeared first on Amazing Health Advances.

New Test Can Rapidly & Accurately Diagnose Bacterial Meningitis

The AHA! Team — Mon, 14 Jul 2025 05:36:55 +0000

Amsterdam University Medical Center via News-Medical – The distinction between bacterial meningitis and similar conditions is often difficult for doctors. Until now, reliable diagnostic tests that could quickly distinguish were lacking. Researchers at Amsterdam UMC have developed a new diagnostic test that can quickly and accurately diagnose bacterial meningitis. The test measures the CRP protein in cerebrospinal fluid, a protein that is already often tested in blood to detect bacterial infections. Research shows that elevated CRP in cerebrospinal fluid is a very reliable indicator of bacterial meningitis. Currently it often takes a long time before meningitis is diagnosed, which delays the start of adequate treatment. The study is published today in The Lancet Regional Health Europe. Bacterial meningitis is a life-threatening condition in which one in six patients die and half of the survivors have residual symptoms. Thus, prompt diagnosis and treatment are crucial. The distinction between bacterial meningitis and similar conditions is often difficult for doctors. Until now, reliable diagnostic tests that could quickly distinguish were lacking.” – Matthijs Brouwer, last author and Amsterdam UMC neurologist Reliable indicator Researchers at Amsterdam UMC have discovered that the CRP protein in cerebrospinal fluid is a very reliable indicator of bacterial meningitis. CRP is already frequently tested in blood to detect bacterial infections, but the value of this test in cerebrospinal fluid had not been well researched until now. After previous successful laboratory tests, the researchers now showed that the device that measures CRP in blood is also sensitive enough to measure CRP in cerebrospinal fluid. “It is a huge gain that the existing infrastructure of the laboratory can be used for the CRP measurements in cerebrospinal fluid. As a result, the test result is already known half an hour after the epidural and the correct treatment of the patient can therefore be started quickly,” says Brouwer. Daily practice Since June 2024, the new test has been used in the daily practice of the Amsterdam UMC. In the study published today, researchers describe how the test was introduced and how effective it is in practice. “Our results show that all patients with bacterial meningitis had an elevated CRP in their cerebrospinal fluid. This was the case in only a few patients without bacterial meningitis, ” adds Brouwer. The test also proved reliable in additional studies in children and patients from at Aalborg University Hospital in Denmark. Broad application in hospitals It is expected that more hospitals will adopt the test, because it can easily be performed in laboratories with existing equipment. The test only costs between three and five euros, providing an affordable and accessible solution to diagnose and treat bacterial meningitis faster. “Any laboratory in which CRP is measured in blood can introduce this test for cerebrospinal fluid tomorrow. We could not have predicted in advance that a new diagnostic test would be used in patients within a year of its discovery,” concludes Brouwer. Source: Amsterdam University Medical Center Journal reference: Olie, S. E., et al. (2025). Validation and clinical implementation of cerebrospinal fluid C-reactive protein for the diagnosis of bacterial meningitis: a prospective diagnostic accuracy study. The Lancet Regional Health – Europe. doi.org/10.1016/j.lanepe.2025.101309. To read the original article click here.

The post New Test Can Rapidly & Accurately Diagnose Bacterial Meningitis appeared first on Amazing Health Advances.

Blood thinners: A Leading Cause of Death in Emergency Rooms

The AHA! Team — Wed, 25 Sep 2024 08:09:07 +0000

Lori Alton via NaturalHealth365 – Anticoagulants, also known as blood thinners, have been around for many decades. These medications have been used for a variety of conditions and situations where there is a risk of clot formation. Clot formation can lead to serious complications such as stroke, heart attack, and deep vein thrombosis (DVT). But at what cost? Blood thinners come in many types – intravenous drugs like heparin and medications taken by mouth like warfarin and Pradaxa. Since blood thinners are considered a ‘preventative’ medication, many doctors prescribe them, believing the benefits outweigh the risks. However, a cardiologist from Duke University notes that blood thinners like warfarin are actually one of the leading causes of death in United States emergency rooms. Therefore, it is important to fully understand the dangerous side effects of warfarin and other blood thinners before blindly accepting a doctor’s prescription for these medications. Anticoagulants: Lifesavers or lethal lottery? The side effects of warfarin are many and include fever, diarrhea, vomiting blood, dizziness, bruising, black or bloody stools, blood in urine, heavy menstrual bleeding, and tissue death (necrosis). Each of these scary symptoms could signify internal bleeding and require immediate emergency medical attention. In fact, the drug’s links to increased bleeding risk and death forced manufacturers to add a ‘black box’ to the product’s label in 2006 that warns of the potentially deadly side effects of warfarin. For many decades, warfarin was the only option for administering blood thinners. In 2010, the U.S. Food and Drug Administration (FDA) approved a new type of blood thinner: Pradaxa. It was supposed to be easier to take than warfarin, just as effective, and still cause fewer side effects. Since the approval of Pradaxa (dabigatran) in 2010, several additional novel oral anticoagulants (NOACs) have been approved in the United States. Rivaroxaban (Xarelto): Approved by the FDA in 2011. Apixaban (Eliquis): Approved in 2012. Edoxaban (Savaysa): Approved in 2015. Betrixaban (Bevyxxa): Approved in 2017, specifically for extended prophylaxis of venous thromboembolism in hospitalized patients. The life-threatening side effects of blood thinners The introduction of NOACs promised a new era in blood clot prevention. However, these drugs come with their own set of potentially life-threatening risks. NOACs, including drugs like Pradaxa, Xarelto, Eliquis, and Savaysa, often cause alarming side effects. Patients frequently report bloody stools, vomiting blood, and severe digestive issues such as diarrhea, nausea, and stomach pain. Other reported side effects include dizziness, fainting, rapid heartbeat, hives, difficulty breathing, and chest tightness. The most severe risk associated with NOACs is internal bleeding, which can be fatal. In 2011, an FDA review of adverse events revealed a concerning statistic: Pradaxa, the first approved NOAC, was associated with a high number of deaths and injuries. The numbers were significant – hundreds of fatalities and thousands of serious events were reported. However, it’s important to note that this data was specific to Pradaxa and not representative of all NOACs, some of which were approved later. Nonetheless, there’s no (good) reason why pharmaceutical companies should be allowed to operate this way with such troubling safety records. The so-called “safety” of these drugs is nothing compared to the potential dangers. Ongoing litigation claims that manufacturers failed to adequately warn doctors about the lack of reversal agents for uncontrolled bleeding in some of these medications. Moreover, many patients remain unaware that NOACs can interact dangerously with other medications and pose heightened risks for those with conditions like kidney disease. The takeaway is clear: no one should prescribe or take anticoagulants without fully understanding every possible complication. As the adage goes, “Let the buyer beware.” We urge you to be fully informed before making any healthcare decisions involving these powerful and potentially dangerous drugs. Sources for this article include: NIH.gov NIH.gov DrugWatch.com DrugWatch.com Reuters.com To read the original article click here.

The post Blood thinners: A Leading Cause of Death in Emergency Rooms appeared first on Amazing Health Advances.

Artificial Veins Could Boost Success of Organ Transplants

The AHA! Team — Fri, 14 Jun 2024 08:24:03 +0000

Zachy Hennessey via Israel21c – Bonus Biogroup has developed microscopic biodegradable tubes that run through an engineered transplant organ, supplying a steady flow of blood. Globally, there is a persistent shortage of viable organs for transplantation. This unmet need has spurred the development of “engineered organs” — cultivated tissue that mimics the structure and function of livers, hearts, lungs and other vital viscera. While these in-vitro inside parts can be used to fill the gap in organ supply, it’s really hard to supply blood throughout the newly transplanted tissue. To solve this problem, Bonus Biogroup, an Israeli biotechnology company specializing in next-generation tissue regeneration therapies, has developed a method of producing a sophisticated network of artificial blood vessels that will enable reliable blood flow to transplanted artificial organs, drastically increasing their viability. Tomer Bronshtein, VP of Business Development at Bonus Biogroup, elaborates on the issue it aims to resolve. “One of the biggest challenges in implementing engineered tissue is making sure that it is vascularized. If it isn’t, only the periphery of the tissue which is exposed to blood vessels will be nourished,” he tells ISRAEL21c. “Now, the body knows how to build blood vessels into new tissue, but this process takes time. After two or three days, if the new tissue is deprived of nutrients, these cells will die,” he says. “Even if the immune matching is superb — even if you could take it from your twin brother — if it’s not vascularized, it will not work.” You’re so vein Enter the Haifa-based company’s latest product: a network of microscopic biodegradable tubes that run throughout an engineered organ, acting as a “scaffold” that holds the cultivated cells together while supplying a steady flow of blood throughout the transplanted tissue. Thanks to its biodegradable qualities, the scaffold ensures the newly embedded organ gets a steady flow of blood until the body replaces the artificial veins with the real deal, at which point it decays and makes its way out of the system. The blood vessels are created through a process called “electrospinning,” which Bronshtein compares to the process of making cotton candy. “There you have sugar that is making fibers because of heat. In electrospinning, you have biomaterials that are making fibers as a result of an electric current,” he says. The cultivated vessels can be spun to customizable diameters ranging from single microns to tens of microns. The artificial bundle of veins hooks up to the body’s blood supply via a port bundled at one end, spreads throughout the transplanted organ, and comes together at the other end into another port hooked up to the body. Picture an apartment building that has one water main which then splits into pipes that run through every floor of the building, and then they all meet back up again to head into the sewer system. Bonus Biogroup made that plumbing system, but for in-vitro organs. Enough to grow around As of 2022, the engineered tissues market was valued at approximately $12 billion and is projected to grow at an annual rate of about 11%, reaching $33 billion by 2032. Bonus Biogroup is banking on its innovation helping this market reach even greater potential. The company’s bone grafting product, BonoFill, stands to serve around 6.2 million patients in the US alone. By utilizing accessible and cost-effective methods, the company can streamline production processes and make its technology more widely accessible, while maintaining its competitive edge through patent protection. The publicly-traded company, which employs 53 people, has obtained patent approvals in 17 European countries and England, safeguarding Bonus Therapeutics, its wholly-owned subsidiary, until 2036. To date, the company has raised $60 million, and it stands to serve around 6.2 million patients in the US alone with its bone grafting product, BonoFill. With that in mind, Bonus intends to grant access to its technology to anyone who wants to use it — so long as they go through the proper legal channels. “This technology is something that we have no intention to keep to ourselves. Once we have established the global patent coverage on this technology, we are able to extend its use to other potential users,” says Bronshtein. While the company is using its vascular network primarily for its prior products — engineered bone and soft tissue for transplantation — it could be used for other needs as well. “Our goal is to make it the first available choice to patients in any indication,” notes CEO Shai Meretzki. “We know that there are groups in the world trying to do what we’ve done and failing to do it. And we are willing to allow them to use the technology developed by us within their products.” “It’s like how only one company developed the Intel chip, but you can find that chip in many devices. It’s the same concept here. You can put our blood network inside a liver or kidney or pancreas or any other tissue. Because the market is so wide, we are willing to share it,” Meretzki says. “When we founded Bonus, we were looking for a real change. Our goal from scratch was to create blockbuster products that will treat millions in each indication. And I believe that’s exactly what we are doing.” To read the original article click here.

The post Artificial Veins Could Boost Success of Organ Transplants appeared first on Amazing Health Advances.

As Number of COVID-19 Infections Drop, the President Announces FDA-Authorized Plasma Treatment

AHA Publisher — Tue, 25 Aug 2020 07:00:05 +0000

News Staff via CBN News – There’s some good news in the fight against the Coronavirus. The number of new infections has dropped to the lowest level in two months. The news comes as President Trump and the Food and Drug Administration announced progress Sunday in treating COVID-19. So far, the virus has killed more than 175,000 Americans. The FDA declared emergency use authorization for convalescent plasma for COVID-19 patients, saying its benefits outweigh its risks. Convalescent plasma is blood from people who have survived the virus which is then transfused into people currently fighting it. It’s been used on 70,000 people since the pandemic began. The treatment is a century-old approach to fend off flu and measles before vaccines. It’s a go-to tactic when new diseases come along, and history suggests it works against some, but not all, infections. President Trump said the emergency use authorization will dramatically increase access to the treatment. But the FDA’s chief scientist says the treatment should not be recognized as a new standard for treating Coronavirus patients. In a letter describing the emergency authorization, the chief scientist for the FDA, Denise Hinton, said: “COVID-19 convalescent plasma should not be considered a new standard of care for the treatment of patients with COVID-19. Additional data will be forthcoming from other analyses and ongoing, well-controlled clinical trials in the coming months. According to the Associated Press, the White House had grown agitated with the pace of the plasma approval. The accusations of an FDA slowdown, which were presented without evidence, were just the latest assault from Trump’s team on what he refers to as the “deep state” bureaucracy. White House chief of staff Mark Meadows did not deal in specifics, but said that “we’ve looked at a number of people that are not being as diligent as they should be in terms of getting to the bottom of it.” “This president is about cutting red tape,” Meadows said in an interview Sunday on “This Week” on ABC. “He had to make sure that they felt the heat. If they don’t see the light, they need to feel the heat because the American people are suffering.” To read the original article click here. For more articles from CBN News click here.

The post As Number of COVID-19 Infections Drop, the President Announces FDA-Authorized Plasma Treatment appeared first on Amazing Health Advances.

New Blood, New Hope: Transfusions Protect the Brain from Stroke Damage

AHA Publisher — Sat, 22 Aug 2020 07:00:54 +0000

West Virginia University via EurekAlert – Muscle weakness permeates through one side of your body and your speech slurs. It’s a stroke. And you need to be rushed to the emergency room. Doctors replace your blood with the blood of a healthy person who’s never suffered a stroke. This blood swap lessens damage to your brain, and any neurological deficits from the stroke are nil. This is not mere wishful thinking. It is a potential breakthrough in stroke therapy based on mice research by West Virginia University neuroscientists. In the study, led by Xuefang “Sophie” Ren, research assistant professor in the Department of Neuroscience, the team found that blood substitution therapy rescues the brains of mice from ischemic damage. Their article is published in Nature Communications. “What we were able to demonstrate is that if you remove part of the blood from a subject undergoing stroke, and replace that blood from a subject that’s never had a stroke, the outcomes of that stroke are profoundly improved,” said Ren, who’s also director of the WVU Experimental Stroke Core. The study is believed to be the first to show that blood replacement therapy leads to improved stroke outcomes in mice, a potential next step for stroke therapy in humans. Most strokes (ischemic) occur when the blood supply to the brain is interrupted, usually by a blockage of the arteries leading to the brain. While there is no known single medication for stroke, the only FDA-approved treatment for ischemic strokes is tPA, or tissue plasminogen activator, which dissolves the clot and improves blood flow. However, tPA typically must be administered within three hours of the stroke. Ren’s research indicates that blood transfusions can take place beyond that limited window – up to seven hours – and still have a positive impact. Replacing 20 percent of the blood in a mouse was enough to show a profound reduction in damage to the brain. The average adult holds around one-and-a-half gallons of blood in the body. The study’s co-authors include Heng Hu, postdoctoral fellow and Experimental Stroke Core surgeon, and James Simpkins, director of the Center for Basic & Translational Stroke Research and professor of the Department of Neuroscience. Out with the old, in with the new “The idea is to change the immune response that happens after stroke,” Simpkins said. Researchers explained that following a stroke, the makeup of a patient’s blood changes, causing disruptions in the brain and how the body responds. Neutrophils, a type of white blood cell that helps lead the immune system’s response, play a role in increasing the levels of an enzyme called MMP-9, which can lead to blood-brain barrier leakage and degeneration in brain tissue. Blood replacement therapy removes inflammatory cells and decreases neutrophils and MMP-9 levels following a stroke, the study concluded. “The immune system doesn’t recognize much of what’s happening when there’s a stroke,” Simpkins said. “So the neutrophils go to the brain and try to clean up the damage that happens. But there’s too much in the brain and those same neutrophils release MMP-9, which then exacerbates the damage. “What we learn is that stroke is simply not a cerebral vascular event. It’s a whole-body event. Both the brain and the body get signals that something’s going on in the brain and as the immune system responds to try to help, it actually worsens the outcome. Therefore, by removing the blood and replacing it with the blood of those that have not experienced stroke, we get good outcomes.” Currently, blood-based therapies are emerging as treatments to combat aging and fight neurodegenerative diseases, the researchers noted. Now, blood replacement therapy is a proven strategy that targets the pathological systemic responses to stroke, Ren said, and could reduce the mortality of stroke patients. “Blood indeed saves our brains and lives from stroke damage,” she said. According to the Centers for Disease Control and Prevention, more than 795,000 Americans experience a stroke each year and 140,000 die from it. “In an ideal circumstance, a person having a stroke would show up to Ruby (Memorial) or any hospital,” Simpkins said. “They’d go through the proper protocol. We would remove their stroke blood and magically restore it with the right kind of blood that would tamp down this immune response they’re experiencing. If it works out, that’s good for all of us.” To read the original article click here.

The post New Blood, New Hope: Transfusions Protect the Brain from Stroke Damage appeared first on Amazing Health Advances.

We Love Coffee, Tea, Chocolate and Soft Drinks So Much, Caffeine Is Literally in Our Blood

AHA Publisher — Wed, 04 Dec 2019 08:00:49 +0000

Oregon State University via Newswise – Scientists at Oregon State University may have proven how much people love coffee, tea, chocolate, soda and energy drinks as they validated their new method for studying how different drugs interact in the body. Newswise — CORVALLIS, Ore. – In conducting mass spectrometry research, Richard van Breemen and Luying Chen worked with various biomedical suppliers to purchase 18 batches of supposedly pure human blood serum pooled from multiple donors. Biomedical suppliers get their blood from blood banks, who pass along inventory that’s nearing its expiration date. All 18 batches tested positive for caffeine. Also, in many of the samples the researchers found traces of cough medicine and an anti-anxiety drug. The findings point to the potential for contaminated blood transfusions, and also suggest that blood used in research isn’t necessarily pure. “From a ‘contamination’ standpoint, caffeine is not a big worry for patients, though it may be a commentary on current society,” said Chen, a Ph.D. student. “But the other drugs being in there could be an issue for patients, as well as posing a problem for those of us doing this type of research because it’s hard to get clean blood samples.” The study was published in the Journal of Pharmaceutical and Biomedical Analysis. In addition to caffeine, the research also involved testing pooled serum for alprazolam, an anti-anxiety medicine sold under the trade name Xanax; dextromethorphan, an over-the-counter cough suppressant; and tolbutamide, a medicine used to treat type 2 diabetes. All of the pooled serum was free of tolbutamide, but eight samples contained dextromethorphan and 13 contained alprazolam – possibly meaning that if you ever need a blood transfusion, your odds of also receiving caffeine, cough medicine and an anti-anxiety drug are pretty good. “The study leads you in that direction, though without doing a comprehensive survey of vendors and blood banks we can only speculate on how widespread the problem is,” said van Breemen, the director of OSU’s Linus Pauling Institute. “Another thing to consider is that we found drugs that we just happened to be looking for in doing the drug interaction assay validation – how many others are in there too that we weren’t looking for?” The purpose of the study by Chen and van Breemen was to test a new method for evaluating the potential for interactions between botanical dietary supplements and drug metabolism. The method involves rapid protein precipitation and ultra high pressure liquid chromatography and is being used to support clinical studies. In the clinical studies, participants take a drug cocktail along with a botanical supplement – hops, licorice or red clover – to see if the supplement causes any of the drugs to be metabolized differently than they otherwise would. “Botanicals basically contain natural products with drug-like activities,” van Breemen said. “Just as a drug may alter the drug-metabolizing enzymes, so can natural products. It can become a real problem when someone takes a botanical supplement and is also on prescription drugs – how do those two interact? It’s not straightforward or necessarily predictable, thus the need for methods to look for these interactions. The odd thing in this case was finding all the tainted blood.” Two individual donors who agreed to abstain from caffeinated foods and beverages had to be enlisted so the research could be completed. To read the original article click here.

The post We Love Coffee, Tea, Chocolate and Soft Drinks So Much, Caffeine Is Literally in Our Blood appeared first on Amazing Health Advances.

Saving Lives Faster: World-First Laser Incubator for Blood

AHA Publisher — Sun, 29 Sep 2019 03:18:41 +0000

Monash University via Science Daily – Researchers have developed the world’s first blood incubator using laser technology. This could prevent fatal blood transfusions in critically ill patients and can detect antibodies in pregnant women that can kill a baby in utero. To read the original article and learn more about this world-first blood incubator, click here.

The post Saving Lives Faster: World-First Laser Incubator for Blood appeared first on Amazing Health Advances.